Premier Alternatives

Shenandoah Therapeutics

South San Francisco, CA · Founded 2022 · Privately Held (backing)

Developer of an oncology technology platform designed for cancer treatment. Shenandoah Therapeutics is based in South San Francisco, CA and was founded in 2022. Its last reported valuation was $37 million in Mar 2025. It has raised $21.5 million across 1 recorded round; the latest was a $21.5 million early-stage round in May 2025.

Last reported valuation
$37.0M
Oct 2026
Priced at
—
Total raised
$21.5M
Last round
Early Stage VC
May 2025

Shenandoah Therapeutics key facts

as of Oct 2026
  • Developer of an oncology technology platform designed for cancer treatment.
  • Shenandoah Therapeutics is valued at approximately $37.0M as of Oct 2026 (last reported valuation).
  • It has raised $21.5M across 1 recorded rounds; the latest was Early Stage VC ($21.5M) in May 2025.
  • Notable investors include Samsara BioCapital, Honghui Capital, First Spark Ventures, Time BioVentures, YK Bioventures.
  • Shenandoah Therapeutics has filed 1 Form D with the SEC, most recently May 2025 ($21.5M sold to 12 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$37.0M

Shenandoah Therapeutics's last reported valuation, Mar 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Private Market View
More of Shenandoah Therapeutics with a free Private Market View account
  • ·Watch Shenandoah Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Shenandoah Therapeutics funding rounds

1 rounds
May 2025Early Stage VC$21.5MSEC filing▮
Full funding history →

Shenandoah Therapeutics valuation

Shenandoah Therapeutics's last reported valuation was $37 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.

How much has Shenandoah Therapeutics raised?

Shenandoah Therapeutics has raised $21.5 million across 1 recorded round since 2025. The largest was a $21.5 million early-stage round in May 2025.

Shenandoah Therapeutics has filed 1 Form D with the SEC, most recently in May 2025 ($21.5 million sold to 12 investors).

Shenandoah Therapeutics investors

5 investors are on record for Shenandoah Therapeutics, including Samsara BioCapital, Honghui Capital, First Spark Ventures and Time BioVentures. The early-stage round in May 2025 drew 12 investors.

About Shenandoah Therapeutics

Developer of an oncology technology platform designed for cancer treatment. The company's platform utilizes a combination of proteins, including transcriptional chemical inducers of proximity, which trigger cancer cells to self-destruct, enabling medical professionals to offer new therapeutic options for cancer patients.

Sector
Healthcare
HQ
South San Francisco, CA, United States
Founded
2022
Employees
5
Ownership
Privately Held (backing)

Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.